Latest news with #LydiaAbadFranch
Yahoo
14 hours ago
- Health
- Yahoo
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
STOCKHOLM, June 20, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington (21-25 June). With ten (10) presentations, Sobi's clinical teams will showcase new data for avatrombopag to treat children with ITP, surgery outcomes using efanesoctocog alfa, and abstracts on specific long-term haemophilia studies. "Attending ISTH is an important part of our commitment to collaboration and knowledge sharing so we can further advance treatments for those living with haemophilia, immune thrombocytopenia, and other rare blood conditions", said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. "We are proud to be showcasing abstracts as part of the ISTH programme, including Doptelet abstracts that present new data related to children living with ITP, Altuvoct outcomes for perioperative management, and joint health outcomes from a long-term extension study, as well as final outcomes from the B-MORE study. Many people living with rare conditions have unmet needs, and we are proud to present additional data advancing treatments for these rare conditions." Data to be presented at ISTH 2025 ALTUVOCT® (efanesoctocog alfa) OC 64.4: Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program Presenting author: Liane Khoo Oral presentation Session date: Tuesday 24 June Session time: 14:45 - 16:00 EDT Location: 151 A&B, Walter E. Washington CC Convention Center OC 20.5: Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children: XTEND-ed Second Interim Analysis Presenting author: Lynn Malec Oral presentation Session date: Sunday 22 June Session time: 14:45 - 16:00 EDT Location: Ballroom A-C, Walter E. Washington CC Convention Center PB0847: Minor Surgeries Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program Presenting author: Pratima Chowdary Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall PB1425: Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing XTEND-ed Presenting author: Christoph Königs Poster presentation Session date: Tuesday 24 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall General Haemophilia PB0778: Addressing unmet medical needs and health inequities in haemophilia A: expertconsensus statements Presenting author: Cédric Hermans Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall PB0816: Extravascular distribution of factor IX: evidence and relevance for haemophilia B replacement therapy Presenting author: Cédric Hermans Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall PB1439: Monitoring Joint Health in Haemophilia Patients in Spain: Updated Analysis of the JOIN-US Project Presenting author: María Teresa Álvarez Román Poster presentation Session date: Tuesday 24 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall ALPROLIX® (rFIXFc) PB0868: Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Final Data from the B-MORE Study Presenting author: Heidi Glosli Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall Doptelet® (avatrombopag) PB0348: Consistent Response to Avatrombopag for the Treatment of Children with ITP Across Various Baseline Characteristics Presenting author: Rachael F. Grace Poster presentation Session date: Sunday 22 June Session time: 13:45 - 14:45 EDT Location: Exhibition hall PB0364: Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration Presenting author: Rachael F. Grace Poster presentation Session date: Sunday 22 June Session time: 13:45 - 14:45 EDT Location: Exhibition hall OC 65.3: Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure Presenting author: Srikanth Nagalla Oral presentation Session date: Tuesday 24 June 2025 Session time: 14:45 – 16:00 EDT (Presentation time currently in programme: 15:15 – 15:30 EDT) All abstracts are accessible through the official ISTH website. However, any late-breaking abstracts will only be made available later. About ALTUVOCT® (efanesoctocog alfa) ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A. ALTUVOCT can be used for all age groups and any disease severity. About Elocta®/Eloctate® (efmoroctocog alfa) Elocta®/Eloctate® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A. Elocta/Eloctate can be used for all age groups. About Alprolix® (eftrenonacog alfa) Alprolix® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B. Alprolix can be used for all age groups. About Doptelet® (avatrombopag) Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. About Sobi Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi's team is guided by one purpose: to chase the miracles of science to improve people's lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi's people and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY About the Sanofi and Sobi collaboration Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or ALTUVIIIO® in the US, Japan, and Taiwan, and Altuvoct in Europe. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: Sobi will showcase extensive research and clinical outcomes at ISTH 2025 View original content:
Yahoo
28-05-2025
- Business
- Yahoo
Sobi to share new clinical data and research at EULAR 2025
STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include clinical trial outcomes on the efficacy and safety of Gamifant in the treatment of macrophage activating syndrome, updates on trial details of Vonjo investigating the potential treatment of VEXAS, and an analysis on the management of uncontrolled gout. Sobi will host a symposium on the dermatologic, rheumatologic, and hematologic features of VEXAS syndrome during the congress. The symposium will be chaired by Dr Sophie Georgin-Lavialle MD, PhD from the French National Reference Centre for auto-inflammatory diseases and inflammatory amyloidosis. The symposium will be followed by a panel discussion and Q&A. "We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi. "With several poster and oral presentations and a longer form symposium, we are proud to be able to show how research and collaboration can advance clinical practice – and we look forward to meeting and connecting with colleagues in Barcelona," Lydia Abad-Franch concluded. Key data to be presented at EULAR 2025 Gamifant (emapalumab) Efficacy and Safety of emapalumab in Patients with Macrophage Activation Syndrome in Still's disease: Results from a Pooled Analysis of Two Prospective Trials Speaker: Professor Fabrizio De Benedetti (principal investigator of the study) Oral presentation Session title: Clinical Abstract Session: Proceedings in Juvenile Idiopathic Arthritis Session date: Thursday 12 June Session time: 10:30 - 12:00 CEST Presentation time: 10:48 - 10:57 CEST Location: Room 6.1 Exposure-safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still's disease Speaker: Professor Fabrizio De Benedetti (principal investigator of the study) Poster presentation Session title: Poster View VI Session date: Friday 13 June Session time: 12:00 – 13:30 CEST Location: Poster Hall NASP (formerly SEL-212) Variations in uncontrolled gout between Rheumatologists and Nephrologists Poster presentation Session title: Poster View VIII Session date: Friday 13 June Session time: 10:15 - 11:45 CEST Location: Poster Hall Vonjo (pacritinib) Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research Poster presentation Session title: Poster View VII Session date: Friday 13 June Session time: 14 :45 - 15 :45 CEST Location: Poster Hall PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome Poster tour Session Title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS Session date: Saturday 14 June Session time: 10:15 -11:45 CEST Presentation time: 10:29 - 10:36 CEST (4 mins + 2 mins Q&A) Location: Poster Tour II Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI) Poster tour Session title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS Session date: Saturday 14 June Session time: 10:15 - 11:45 CEST Presentation time: 10:43 - 10:50 CEST (4 mins + 2 mins Q&A) Location: Poster Tour II Medical Symposium An in-depth presentation on VEXAS syndrome: the dermatologic, rheumatologic, and hematologic features of the condition. Followed by a panel discussion and Q&A Symposium title: Putting on your VEXAS goggles: Seeing what's in plain sight Session date: Friday 13 June Session time: 17:30 - 18:30 CEST Location: Fira de Barcelona, Room B4 About Gamifant® (emapalumab) Gamifant® (emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. About Macrophage activation syndrome (MAS) Macrophage activation syndrome (MAS) is a potentially life-threatening complication of Still's disease characterised by interferon-gamma (IFNγ)–driven systemic hyperinflammation. More than one-third of patients inadequately respond to high-dose glucocorticoids. Emapalumab, an anti-IFNγ antibody, demonstrated efficacy and safety in a phase 2 pilot study in patients with MAS in Still's disease and an inadequate response to high-dose glucocorticoids. About NASP, formerly SEL-212 NASP is a novel investigational medicine designed to reduce serum urate (SU) levels in people with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid. ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout. About VONJO® (pacritinib) VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). About VEXAS VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene of blood cells and acquired later in life. The condition is not genetically inherited. About Sobi Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: Sobi share New clinical Data and Research at EULAR 2025 View original content:
